Novo Nordisk posts results for two semaglutide trials, opens new NNC0487-0111 study

Novo Nordisk had an active week of registry updates, with results posted for two completed trials and a new Phase 1 study opening for recruitment.

• OASIS 2, a Phase 3 trial of oral semaglutide 50 mg once daily in East Asian participants with overweight or obesity¹, was marked completed with results posted August 14, 2026. The study enrolled 201 participants¹ and its primary outcome was percent change from baseline in body weight, measured at baseline (week 0) and week 68¹.
• REALYSE, a Phase 4 trial comparing RYBELSUS® to other medicines in people with type 2 diabetes, looking at how well RYBELSUS® lowers blood sugar compared to other tablets when used in addition to metformin², was completed with results posted August 10, 2026. The trial enrolled 1018 participants² and its primary outcome was change in glycated haemoglobin (HbA1c) from week 0 to year 1².
• A new Phase 1 study of once-weekly subcutaneous NNC0487-0111 evaluating how the compound affects the amount of energy the body uses in people living with obesity following weight loss³ began recruiting, comparing it against a low-calorie diet or placebo. The trial has an estimated enrollment of 120 participants³ and its primary outcome is change in sleeping metabolic rate (SMR) from baseline (week 0) to week 12-26, measured in kilojoules per day³.